BorisB thanks for expressing your thoughts, as it always helps to have difference of views on DRIO and its tech and their customers/users opinions and thoughts. This is just the kind of dialogue any company or enterprise should be on the outlook for. As one grows older, they slow and start to lose skills and positive perceptions of life. This is just natural . . . aging can be thought of as a disease AND an adventure.
Like a friend of mine that can just still drive safety (has Type 2 Diabetes fro several decades), has an advanced medical degree, and 70+ told me . . . you have to start watching things like going round barefooted (danger of foot wound and bad news for infection). He really is up on his self-care and doing great psychologically. But with all his experience in his field of working with customers, he is 'jaded' on new diabetic tech like portable oral breather insulin pump.
I take a middle-of-road position on customer/user acceptance of new ideas and techs (though I may be all for them), as a retail investor. Note Today's Tesla EV news about results of opening sales in China. Jim Cramer, on his TV finance Show . . . said Tesla great car, but Elon Musk bad businessman. Oh . . . really . . . solid advice from person who has never displayed huge tech skills or degreed experience. But Cramer will have effect on investor sentiment toward Tesla.
My friend has told me of several elderly diseased persons, who DENIED their own medical car case advice and refused to properly take care of themselves, resulting in their further disability and death. <---this psycho-denial is very much a part of disease personal care, especially for those who are weak and suffering a loss of self-freedom. And, not all diabetics have family now, nor caring friends still alive? All I am saying is this is some part of the Diabetes Equation, and potential issues in customer/user-ship.
And, DRIO does have the potential to take diabetic care to another level. Lets see how this company manages its product/service introduction, advertising, orders, revenues, FDA Approval progress, and needed new funding sources.
